|
1
|
Kumar P, Pradhan K, Karunya R, Ambasta RK
and Querfurth HW: Cross-functional E3 ligases Parkin and C-terminus
Hsp70-interacting protein in neurodegenerative disorders. J
Neurochem. 120:350–370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yan S, Sun X, Xiang B, Cang H, Kang X,
Chen Y, Li H, Shi G, Yeh ET, Wang B, et al: Redox regulation of the
stability of the SUMO protease SENP3 via interactions with CHIP and
Hsp90. EMBO J. 29:3773–3786. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Seo J, Lee EW, Sung H, Seong D,
Dondelinger Y, Shin J, Jeong M, Lee HK, Kim JH, Han SY, et al: CHIP
controls necroptosis through ubiquitylation- and lysosome-dependent
degradation of RIPK3. Nat Cell Biol. 18:291–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paul I and Ghosh MK: The E3 ligase CHIP:
Insights into its structure and regulation. Biomed Res Int.
2014:9181832014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Edkins AL: CHIP: A co-chaperone for
degradation by the proteasome. Subcell Biochem. 78:219–242. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wei Q, Sha Y, Bhattacharya A, Abdel Fattah
E, Bonilla D, Jyothula SS, Pandit L, Hershey GK Khurana and Eissa
NT: Regulation of IL-4 receptor signaling by STUB1 in lung
inflammation. Am J Respir Crit Care Med. 189:16–29. 2014.PubMed/NCBI
|
|
7
|
Kajiro M, Hirota R, Nakajima Y, Kawanowa
K, So-ma K, Ito I, Yamaguchi Y, Ohie SH, Kobayashi Y, Seino Y, et
al: The ubiquitin ligase CHIP acts as an upstream regulator of
oncogenic pathways. Nat Cell Biol. 11:312–319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gaude H, Aznar N, Delay A, Bres A,
Buchet-Poyau K, Caillat C, Vigouroux A, Rogon C, Woods A, Vanacker
JM, et al: Molecular chaperone complexes with antagonizing
activities regulate stability and activity of the tumor suppressor
LKB1. Oncogene. 31:1582–1591. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hatakeyama S, Watanabe M, Fujii Y and
Nakayama KI: Targeted destruction of c-Myc by an engineered
ubiquitin ligase suppresses cell transformation and tumor
formation. Cancer Res. 65:7874–7879. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ruckova E, Muller P, Nenutil R and
Vojtesek B: Alterations of the Hsp70/Hsp90 chaperone and the
HOP/CHIP co-chaperone system in cancer. Cell Mol Biol Lett.
17:446–458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ciocca DR and Calderwood SK: Heat shock
proteins in cancer: Diagnostic, prognostic, predictive, and
treatment implications. Cell Stress Chaperones. 10:86–103. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang T, Yang J, Xu J, Li J, Cao Z, Zhou L,
You L, Shu H, Lu Z, Li H, et al: CHIP is a novel tumor suppressor
in pancreatic cancer through targeting EGFR. Oncotarget.
5:1969–1986. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Ren F, Wang Y, Feng Y, Wang D, Jia
B, Qiu Y, Wang S, Yu J, Sung JJ, et al: CHIP/Stub1 functions as a
tumor suppressor and represses NF-κB-mediated signaling in
colorectal cancer. Carcinogenesis. 35:983–991. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia
X, He S, Qiang F, Li A, Shu Y, et al: CHIP functions as a novel
suppressor of tumour angiogenesis with prognostic significance in
human gastric cancer. Gut. 62:496–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ying Z, Haiyan G and Haidong G: BAG5
regulates PTEN stability in MCF-7 cell line. BMB Rep. 46:490–494.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahmed SF, Deb S, Paul I, Chatterjee A,
Mandal T, Chatterjee U and Ghosh MK: The chaperone-assisted E3
ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN
for proteasomal degradation. J Biol Chem. 287:15996–16006. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan M, Yang X, Wang L, Clark D, Zuo H, Ye
D, Chen W and Zhang P: Plasma membrane proteomics of tumor spheres
identify CD166 as a novel marker for cancer stem-like cells in head
and neck squamous cell carcinoma. Mol Cell Proteomics.
12:3271–3284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lv Z, Wu X, Cao W, Shen Z, Wang L, Xie F,
Zhang J, Ji T, Yan M and Chen W: Parathyroid hormone-related
protein serves as a prognostic indicator in oral squamous cell
carcinoma. J Exp Clin Cancer Res. 33:1002014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ren A, Yan G, You B and Sun J:
Down-regulation of mammalian sterile 20-like kinase 1 by heat shock
protein 70 mediates cisplatin resistance in prostate cancer cells.
Cancer Res. 68:2266–2274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lv Y, Song S, Zhang K, Gao H and Ma R:
CHIP regulates AKT/FoxO/Bim signaling in MCF7 and MCF10A cells.
PLoS One. 8:e833122013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choi YN, Lee SK, Seo TW, Lee JS and Yoo
SJ: C-Terminus of Hsc70-interacting protein regulates profilin1 and
breast cancer cell migration. Biochem Biophys Res Commun.
446:1060–1066. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jang KW, Lee KH, Kim SH, Jin T, Choi EY,
Jeon HJ, Kim E, Han YS and Chung JH: Ubiquitin ligase CHIP induces
TRAF2 proteasomal degradation and NF-κB inactivation to regulate
breast cancer cell invasion. J Cell Biochem. 112:3612–3620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jan CI, Yu CC, Hung MC, Harn HJ, Nieh S,
Lee HS, Lou MA, Wu YC, Chen CY, Huang CY, et al: Tid1, CHIP and
ErbB2 interactions and their prognostic implications for breast
cancer patients. J Pathol. 225:424–437. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yi X, Wei W, Wang SY, Du ZY, Xu YJ and Yu
XD: Histone deacetylase inhibitor SAHA induces ERalpha degradation
in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and
inhibits survival signaling. Biochem Pharmacol. 75:1697–1705. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Raja SM, Clubb RJ, Bhattacharyya M, Dimri
M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M, Band
V, et al: A combination of Trastuzumab and 17-AAG induces enhanced
ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation
and cytotoxicity in ErbB2-overexpressing breast cancer cells.
Cancer Biol Ther. 7:1630–1640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang SA, Cho HS, Yoon JB, Chung IK and Lee
ST: Hsp90 rescues PTK6 from proteasomal degradation in breast
cancer cells. Biochem J. 447:313–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jeong JH, An JY, Kwon YT, Li LY and Lee
YJ: Quercetin-induced ubiquitination and down-regulation of
Her-2/neu. J Cell Biochem. 105:585–595. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JS and Yoo SJ: C-terminus of
Hsc70-interacting protein regulates C-terminal binding protein 2
and the expression of its target genes. Biochem Biophys Res Commun.
432:418–424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schulz R, Marchenko ND, Holembowski L,
Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M and Moll UM:
Inhibiting the HSP90 chaperone destabilizes macrophage migration
inhibitory factor and thereby inhibits breast tumor progression. J
Exp Med. 209:275–289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sarkar S, Brautigan DL, Parsons SJ and
Larner JM: Androgen receptor degradation by the E3 ligase CHIP
modulates mitotic arrest in prostate cancer cells. Oncogene.
33:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiao M, Yan M, Zhang J, Xu Q, Qi S, Wang X
and Chen W: Cancer stem-like cell related protein CD166 degrades
through E3 ubiquitin ligase CHIP in head and neck cancer. Exp Cell
Res. 353:46–53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsuchiya M, Nakajima Y, Waku T, Hiyoshi H,
Morishita T, Furumai R, Hayashi Y, Kishimoto H, Kimura K and
Yanagisawa J: CHIP buffers heterogeneous Bcl-2 expression levels to
prevent augmentation of anticancer drug-resistant cell population.
Oncogene. 34:4656–4663. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Paul I, Ahmed SF, Bhowmik A, Deb S and
Ghosh MK: The ubiquitin ligase CHIP regulates c-Myc stability and
transcriptional activity. Oncogene. 32:1284–1295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McDonough H and Patterson C: CHIP: A link
between the chaperone and proteasome systems. Cell Stress
Chaperones. 8:303–308. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Murata S, Chiba T and Tanaka K: CHIP: A
quality-control E3 ligase collaborating with molecular chaperones.
Int J Biochem Cell Biol. 35:572–578. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsuchiya M, Nakajima Y, Hirata N,
Morishita T, Kishimoto H, Kanda Y and Kimura K: Ubiquitin ligase
CHIP suppresses cancer stem cell properties in a population of
breast cancer cells. Biochem Biophys Res Commun. 452:928–932. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Muller P, Ruckova E, Halada P, Coates PJ,
Hrstka R, Lane DP and Vojtesek B: C-terminal phosphorylation of
Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP
and HOP to determine cellular protein folding/degradation balances.
Oncogene. 32:3101–3110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ghadban T, Jessen A, Reeh M, Dibbern JL,
Mahner S, Mueller V, Wellner UF, Güngör C, Izbicki JR and Vashist
YK: In vitro study comparing the efficacy of the
water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of
the nonwater-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell
lines. Int J Mol Med. 38:1296–1302. 2016.PubMed/NCBI
|
|
39
|
Haque A, Alam Q, Alam MZ, Azhar EI, Sait
KH, Anfinan N, Mushtaq G, Kamal MA and Rasool M: Current
understanding of HSP90 as a novel therapeutic target: An emerging
approach for the treatment of cancer. Curr Pharm Des. 22:2947–2959.
2016. View Article : Google Scholar : PubMed/NCBI
|
